STEVEN EVERSLEY: Open Payments
NPI 1144205865 · ELLICOTT CITY, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,858 in 84 payments from 23 companies in 2025. Trend: 2023 $1,503 · 2024 $1,726 · 2025 $1,858
Food & beverage: $1,858
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $267 |
| Novo Nordisk Inc | 9 | $218 |
| Lilly USA, LLC | 8 | $158 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $127 |
| PFIZER INC. | 5 | $124 |
| AstraZeneca Pharmaceuticals LP | 5 | $101 |
| Merck Sharp & Dohme LLC | 4 | $100 |
| Amgen Inc. | 5 | $99 |
| Sumitomo Pharma America, Inc. | 4 | $91 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $88 |
Products named: JARDIANCE, VRAYLAR, Ozempic, NURTEC ODT, GEMTESA, Kerendia, LEQVIO, Veozah.
Industry payments across MD — which companies pay providers there.
